DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

An Observational Study on the Sorin Group New Brady Leads XFine and Beflex

Information source: Sorin Group
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pacing Leads Implantation

Phase: N/A

Status: Recruiting

Sponsored by: Sorin Group

Official(s) and/or principal investigator(s):
Henri Benkemoun, MD, Principal Investigator, Affiliation: Unité de Cardiologie et Rythmologie Interventionelle, Perpignan France

Overall contact:
Alberto BORRI, Phone: 00390161487211, Email: Alberto.borri@sorin.com


This observational study is a non-interventional multi-centre, prospective study.

The aim of the study is to evaluate the Sorin Group new passive- and active- fixation pacing leads. We plan to assess the acute and short term lead dislodgment rate (within the first three months following implantation) correlated with the type of lead (active- or passive- fixation). Further, we are collecting data related to leads handling and leads electrical performances

Clinical Details

Official title: Performance of the New Generation of Sorin Group Brady Leads In a Normal Hospital Practice

Study design: Observational Model: Cohort, Time Perspective: Prospective

Detailed description: The primary objective of this observational study is to assess the acute rate of dislodgment of the new Sorin group range of active- and passive- fixation leads up to 3 months following implant.

Assessment of electrical performances (pacing threshold, sensing amplitude, impedance) of the leads at implant and during follow-up.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- The implanted lead must allow the measurement of pacing threshold at 0. 5ms, R-wave or

P-wave amplitude and impedance of the lead.

- Included patients may receive more than one lead under evaluation.

Exclusion Criteria:

- Any contraindication to endocavitary lead implantation;

- Inability to understand the purpose of the study or refusal to co-operate.

- Geographically unstable or unavailability for scheduled M1-M3 follow-up at the

implanting centre as defined in the investigational plan.

- Patient of minor age (<18)

- Pregnancy.

Locations and Contacts

Alberto BORRI, Phone: 00390161487211, Email: Alberto.borri@sorin.com

Clinique St Pierre, Perpignan, France; Recruiting
Henri Benkemoun, MD
Henri Benkemoun, MD, Principal Investigator
Additional Information

Starting date: July 2008
Last updated: July 22, 2010

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015